Promosyon programı Protara Therapeutics, Inc.
Gelişmiş program
Basit grafik
Şirket hakkında Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. daha fazla ayrıntı| IPO date | 2014-10-22 |
|---|---|
| ISIN | US74365U1079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.protaratx.com |
| Цена ао | 4.53 |
| Günlük fiyat değişimi: | +0.8811% (4.54) |
|---|---|
| Haftalık fiyat değişimi: | -0.4348% (4.6) |
| Aylık fiyat değişimi: | +30.86% (3.5) |
| 3 ayda fiyat değişimi: | -16.88% (5.51) |
| Altı ayda fiyat değişimi: | +150.27% (1.83) |
| Yıllık fiyat değişimi: | +14.21% (4.01) |
| 3 yılda fiyat değişimi: | -18.21% (5.6) |
| 5 yılda fiyat değişimi: | -83.63% (27.98) |
| Yılbaşından bu yana fiyat değişimi: | -13.26% (5.28) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| Kurumlar | Hacim | Paylaşmak, % |
|---|---|---|
| Opaleye Management Inc. | 2692594 | 23.55 |
| Vanguard Group Inc | 427612 | 3.74 |
| Boxer Capital, LLC | 209227 | 1.83 |
| Baker Brothers Advisors, LLC | 199671 | 1.75 |
| Ikarian Capital, LLC | 188664 | 1.65 |
| Privium Fund Management (UK) Ltd | 119730 | 1.05 |
| Renaissance Technologies, LLC | 113300 | 0.99 |
| Geode Capital Management, LLC | 78518 | 0.69 |
| Bridgeway Capital Management, Inc. | 64000 | 0.56 |
| Citadel Advisors Llc | 38035 | 0.33 |
| ETF | Paylaşmak, % | Yıllık karlılık, % | Temettüler, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00906 | 17.09 | 1.54048 |
| 0.01 | 17.09 | 1.54 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Mr. Jesse Shefferman | Co-founder, CEO, President & Director | 1.02M | 1972 (53 yıl) |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior VP & Chief Scientific Operations Officer | 694.16k | 1981 (44 yıl) |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 696.62k | 1968 (57 yıllar) |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller | N/A | 1991 (34 yıl) |
| Ms. Mary J. Grendell | General Counsel & Corporate Secretary | N/A | |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
Adres: United States, New York. NY, 345 Park Avenue South - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.protaratx.com
Web sitesi: https://www.protaratx.com
